ASCO GU 2022 - Results from #40

Viewing 41-60 of 316 articles

ASCO GU 2022: The Association of the Use of Anxiety and Depression Medications with PSA Testing

ASCO GU 2022: Comparative Genomic Analyses Between Asian and Caucasian Prostate Cancers in an 80,829 Patient Cohort

ASCO GU 2022: Practice Patterns in the Management of Metastatic Castration-Sensitive Prostate Cancer: A Single-Center Survey-Based Study

ASCO GU 2022: Use of Bone Modifying Agents for Metastatic Castrate-Resistant Prostate Cancer

ASCO GU 2022: Long-Term Safety of Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2022: Kinetics of PSMA PET Uptake in Prostate Cancer Lesions After Radiation Therapy: A Single-Center Retrospective Study

ASCO GU 2022: Current Data on Predictive Biomarkers in Renal Cell Carcinoma

ASCO GU 2022: Germline Mutations of Interests in Renal Cell Carcinoma

ASCO GU 2022: Matching Sequencing Reports With Available Therapies in Renal Cell Carcinoma

ASCO GU 2022: Impact of U.S. Preventative Services Task Force Grade D Recommendation Against PSA Screening on Prostate Cancer Mortality

ASCO GU 2022: First Results of the PROMPT Trial: Precision Oncology Allocation in Patients with Early CRPC Following Routine Molecular Profiling

ASCO GU 2022: First Look at Patient Reported Outcomes from IRONMAN, the International Registry of Men with Advanced Prostate Cancer

ASCO GU 2022: Evolving Real-World Patterns of Practice in mCSPC: The Genitourinary Research Consortium (GURC) National Multicenter Cohort Study

ASCO GU 2022: Adjuvant and Consolidative Therapy in Oligometastatic Renal Cell Carcinoma

ASCO GU 2022: Updates on Clinical Trials in First-Line Metastatic Renal Cell Carcinoma Plus Novel Pathways and Endpoints

ASCO GU 2022: Updates on Clinical Trials in Adjuvant Renal Cell Carcinoma

ASCO GU 2022: SWOG S1931 (PROBE): Phase III Randomized Trial of Immune Checkpoint Inhibitor Combination Regimen with or Without Cytoreductive Nephrectomy in Advanced Renal Cancer

ASCO GU 2022: Implications of Androgen Receptor (AR) Alterations Identified by Genomic Testing of Tissue and Blood from Advanced Prostate Cancer (aPC) Patients

ASCO GU 2022: Transcriptomic Discriminators of Response to Apalutamide in Patients with Prostate Cancer (PC) on Active Surveillance (AS)

ASCO GU 2022: Hospitalizations and Common Infections Among Veterans Treated for Metastatic Prostate Cancer

1
2
3
4
5
6
7
8
9
10